COVID-19
“What we have could be a very powerful weapon against these types of viral outbreaks or pandemics because it isn’t pathogen- or virus-specific and could be broadly relevant in these types of situations,” Gil Van Bokkelen, Ph.D., Athersys CEO, told BioSpace.
A summary of daily Biopharma industry news. Please check out stories that are trending on March 20, 2020.
As the number of diagnosed cases of COVID-19 continues to rise in the United States, Eli Lilly has partnered with the Indiana State Department of Health to accelerate testing for the virus in that state.
FujiFilm itself has not commented on the reports from China, The Guardian noted.
Epidemiologists believe COVID-19 will likely affect millions of people in the U.S. If early prevention efforts are not made Swine Flu Pandemic of 2009.
The company has initiated a late-stage trial assessing its rheumatoid arthritis drug Actemra in patients who have severe COVID-19 caused pneumonia.
The FDA Guidance on Conduct of Clinical Trials of Medical Products During COVID-19 Pandemic, released Wednesday, are “a really good first step in ensuring that clinical trials continue with minimum disruption,” according to Jim Kremidas, executive director of the Association of Clinical Research Professionals (ACRP).
The U.S. Food and Drug Administration approved Abbott’s molecular test for the novel coronavirus that causes COVID-19 under an Emergency Use Authorization.
A summary of daily Biopharma industry news. Please check out stories that are trending on March 19, 2020.
The company isn’t out-and-out saying the drug or any combination drugs with darunavir as a formula might not be effective, but they are saying it’s not based on testing at this time.
PRESS RELEASES